Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 313

1.

Cessation and reduction in alcohol consumption and misuse after psychedelic use.

Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW.

J Psychopharmacol. 2019 May 14:269881119845793. doi: 10.1177/0269881119845793. [Epub ahead of print]

PMID:
31084460
2.

Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.

Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R.

PLoS One. 2019 Apr 23;14(4):e0214377. doi: 10.1371/journal.pone.0214377. eCollection 2019.

3.

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.

Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR.

Am J Drug Alcohol Abuse. 2019;45(2):161-169. doi: 10.1080/00952990.2018.1545024. Epub 2019 Mar 1.

PMID:
30822141
4.

A randomized controlled trial of a manual-only treatment for reduction and cessation of problematic caffeine use.

Sweeney MM, Meredith SE, Juliano LM, Evatt DP, Griffiths RR.

Drug Alcohol Depend. 2019 Feb 1;195:45-51. doi: 10.1016/j.drugalcdep.2018.10.034. Epub 2018 Nov 24.

PMID:
30580203
5.

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.

Barsuglia J, Davis AK, Palmer R, Lancelotta R, Windham-Herman AM, Peterson K, Polanco M, Grant R, Griffiths RR.

Front Psychol. 2018 Dec 6;9:2459. doi: 10.3389/fpsyg.2018.02459. eCollection 2018.

6.

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Johnson MW, Hendricks PS, Barrett FS, Griffiths RR.

Pharmacol Ther. 2019 May;197:83-102. doi: 10.1016/j.pharmthera.2018.11.010. Epub 2018 Dec 4. Review.

PMID:
30521880
7.

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition.

Barrett FS, Carbonaro TM, Hurwitz E, Johnson MW, Griffiths RR.

Psychopharmacology (Berl). 2018 Oct;235(10):2915-2927. doi: 10.1007/s00213-018-4981-x. Epub 2018 Jul 30.

8.

Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.

Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW.

J Psychopharmacol. 2018 Jul;32(7):756-769. doi: 10.1177/0269881118780612. Epub 2018 Jun 25.

PMID:
29938565
9.

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE.

Neuropharmacology. 2018 Nov;142:143-166. doi: 10.1016/j.neuropharm.2018.05.012. Epub 2018 Jun 5. Review.

10.

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR.

Psychopharmacology (Berl). 2018 Feb;235(2):521-534. doi: 10.1007/s00213-017-4769-4. Epub 2017 Nov 7.

11.

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.

Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, Barrett FS, Cosimano MP, Klinedinst MA.

J Psychopharmacol. 2018 Jan;32(1):49-69. doi: 10.1177/0269881117731279. Epub 2017 Oct 11.

12.

Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.

Barrett FS, Robbins H, Smooke D, Brown JL, Griffiths RR.

Front Psychol. 2017 Jul 25;8:1238. doi: 10.3389/fpsyg.2017.01238. eCollection 2017.

13.

Neuroticism is associated with challenging experiences with psilocybin mushrooms.

Barrett FS, Johnson MW, Griffiths RR.

Pers Individ Dif. 2017 Oct 15;117:155-160. doi: 10.1016/j.paid.2017.06.004. Epub 2017 Jun 7.

14.

Potential Therapeutic Effects of Psilocybin.

Johnson MW, Griffiths RR.

Neurotherapeutics. 2017 Jul;14(3):734-740. doi: 10.1007/s13311-017-0542-y. Review.

15.

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.

Barrett FS, Griffiths RR.

Curr Top Behav Neurosci. 2018;36:393-430. doi: 10.1007/7854_2017_474. Review.

16.

The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016.

Barrett FS, Griffiths RR.

Hum Psychopharmacol. 2017 Jan;32(1). doi: 10.1002/hup.2564. No abstract available.

PMID:
28120488
17.

Effects of caffeine on alcohol reinforcement: beverage choice, self-administration, and subjective ratings.

Sweeney MM, Meredith SE, Evatt DP, Griffiths RR.

Psychopharmacology (Berl). 2017 Mar;234(5):877-888. doi: 10.1007/s00213-017-4528-6. Epub 2017 Jan 20.

18.

An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.

Johnson MW, Garcia-Romeu A, Johnson PS, Griffiths RR.

J Psychopharmacol. 2017 Jul;31(7):841-850. doi: 10.1177/0269881116684335. Epub 2017 Jan 18.

19.

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA.

J Psychopharmacol. 2016 Dec;30(12):1181-1197.

20.

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR.

J Psychopharmacol. 2016 Dec;30(12):1279-1295. Epub 2016 Nov 17.

21.

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR.

J Psychopharmacol. 2016 Dec;30(12):1268-1278. Epub 2016 Aug 30.

22.

Long-term follow-up of psilocybin-facilitated smoking cessation.

Johnson MW, Garcia-Romeu A, Griffiths RR.

Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60. doi: 10.3109/00952990.2016.1170135. Epub 2016 Jul 21. Erratum in: Am J Drug Alcohol Abuse. 2017 Jan;43(1):127.

23.

Weekly Energy Drink Use Is Positively Associated with Delay Discounting and Risk Behavior in a Nationwide Sample of Young Adults.

Meredith SE, Sweeney MM, Johnson PS, Johnson MW, Griffiths RR.

J Caffeine Res. 2016 Mar 1;6(1):10-19.

24.

Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Johnson MW, MacLean KA, Caspers MJ, Prisinzano TE, Griffiths RR.

J Psychopharmacol. 2016 Apr;30(4):323-9. doi: 10.1177/0269881116629125. Epub 2016 Feb 15.

25.

Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.

Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, González M, Claramunt J, Barker S, Lomnicka I, Waguespack M, Johnson MW, Griffiths RR, Riba J.

Int J Neuropsychopharmacol. 2016 Jul 5;19(7). pii: pyw016. doi: 10.1093/ijnp/pyw016. Print 2016 Jul.

26.

A brief manualized treatment for problematic caffeine use: A randomized control trial.

Evatt DP, Juliano LM, Griffiths RR.

J Consult Clin Psychol. 2016 Feb;84(2):113-21. doi: 10.1037/ccp0000064. Epub 2015 Oct 26.

27.

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Barrett FS, Johnson MW, Griffiths RR.

J Psychopharmacol. 2015 Nov;29(11):1182-90. doi: 10.1177/0269881115609019. Epub 2015 Oct 6.

28.

Psilocybin, psychological distress, and suicidality.

Hendricks PS, Johnson MW, Griffiths RR.

J Psychopharmacol. 2015 Sep;29(9):1041-3. doi: 10.1177/0269881115598338. No abstract available.

29.

Nicotine reinforcement in never-smokers.

Duke AN, Johnson MW, Reissig CJ, Griffiths RR.

Psychopharmacology (Berl). 2015 Dec;232(23):4243-52. doi: 10.1007/s00213-015-4053-4. Epub 2015 Sep 8.

30.

Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans.

Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, González M, Claramunt J, Barker S, Johnson MW, Griffiths RR, Riba J.

Int J Neuropsychopharmacol. 2015 Jun 5;18(12). pii: pyv065. doi: 10.1093/ijnp/pyv065.

31.

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Garcia-Romeu A, Griffiths RR, Johnson MW.

Curr Drug Abuse Rev. 2014;7(3):157-64.

32.

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR.

J Psychopharmacol. 2014 Nov;28(11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11.

33.

Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential.

Reissig CJ, Harrison JA, Carter LP, Griffiths RR.

Psychopharmacology (Berl). 2015 Mar;232(5):871-83. doi: 10.1007/s00213-014-3721-0. Epub 2014 Sep 9.

34.

Caffeine Use Disorder: A Comprehensive Review and Research Agenda.

Meredith SE, Juliano LM, Hughes JR, Griffiths RR.

J Caffeine Res. 2013 Sep;3(3):114-130. Review.

35.

Caffeine Withdrawal and Dependence: A Convenience Survey Among Addiction Professionals.

Budney AJ, Brown PC, Griffiths RR, Hughes JR, Juliano LM.

J Caffeine Res. 2013 Jun;3(2):67-71.

36.

Comparative abuse liability of GHB and ethanol in humans.

Johnson MW, Griffiths RR.

Exp Clin Psychopharmacol. 2013 Apr;21(2):112-123. doi: 10.1037/a0031692. Epub 2013 Feb 18. Erratum in: Exp Clin Psychopharmacol. 2013 Oct;21(5):374.

37.

Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.

Maclean KA, Leoutsakos JM, Johnson MW, Griffiths RR.

J Sci Study Relig. 2012 Dec;51(4):721-737.

38.

Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.

MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR.

Psychopharmacology (Berl). 2013 Mar;226(2):381-92. doi: 10.1007/s00213-012-2912-9. Epub 2012 Nov 8.

39.

Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Carter LP, Kleykamp BA, Griffiths RR, Mintzer MZ.

Psychopharmacology (Berl). 2013 Mar;226(1):53-63. doi: 10.1007/s00213-012-2883-x. Epub 2012 Oct 25.

40.

Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans.

Carter LP, Reissig CJ, Johnson MW, Klinedinst MA, Griffiths RR, Mintzer MZ.

Drug Alcohol Depend. 2013 Mar 1;128(3):206-13. doi: 10.1016/j.drugalcdep.2012.08.025. Epub 2012 Sep 16.

41.

High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.

Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR.

Psychopharmacology (Berl). 2012 Sep;223(1):1-15. doi: 10.1007/s00213-012-2680-6. Epub 2012 Apr 13. Erratum in: Psychopharmacology (Berl). 2013 Aug;228(3):513.

42.

Characterization of individuals seeking treatment for caffeine dependence.

Juliano LM, Evatt DP, Richards BD, Griffiths RR.

Psychol Addict Behav. 2012 Dec;26(4):948-54. doi: 10.1037/a0027246. Epub 2012 Feb 27.

43.

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Johnson MW, Sewell RA, Griffiths RR.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):132-40. doi: 10.1016/j.drugalcdep.2011.10.029. Epub 2011 Nov 29.

44.

Evaluating Dependence Criteria for Caffeine.

Striley CL, Griffiths RR, Cottler LB.

J Caffeine Res. 2011 Dec;1(4):219-225.

45.

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

MacLean KA, Johnson MW, Griffiths RR.

J Psychopharmacol. 2011 Nov;25(11):1453-61. doi: 10.1177/0269881111420188. Epub 2011 Sep 28.

46.

Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use.

Kleykamp BA, Griffiths RR, McCann UD, Smith MT, Mintzer MZ.

Exp Clin Psychopharmacol. 2012 Feb;20(1):28-39. doi: 10.1037/a0025237. Epub 2011 Sep 19.

47.

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R.

Psychopharmacology (Berl). 2011 Dec;218(4):649-65. doi: 10.1007/s00213-011-2358-5. Epub 2011 Jun 15.

48.

Caffeine choice prospectively predicts positive subjective effects of caffeine and d-amphetamine.

Sigmon SC, Griffiths RR.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):341-8. doi: 10.1016/j.drugalcdep.2011.04.018. Epub 2011 May 19.

49.

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.

Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR.

Drug Alcohol Depend. 2011 May 1;115(1-2):150-5. doi: 10.1016/j.drugalcdep.2010.11.005. Epub 2010 Dec 4.

50.

Intravenous self-administration of γ-hydroxybutyrate (GHB) in baboons.

Goodwin AK, Kaminski BJ, Griffiths RR, Ator NA, Weerts EM.

Drug Alcohol Depend. 2011 Apr 1;114(2-3):217-24. doi: 10.1016/j.drugalcdep.2010.10.006. Epub 2010 Nov 26.

Supplemental Content

Loading ...
Support Center